USP15 and hepatocellular carcinoma: Although we found that USP15 increased the resistance to lenvatinib in HCC, we did not study specimens from patients with HCC treated with lenvatinib, making it impossible for us to objectively evaluate whether USP15 can be used as a marker for targeted treatment resistance to lenvatinib in the clinic.